Company news

PTC Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results

July 28, 2021

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

July 14, 2021

Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

June 23, 2021

Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy

June 22, 2021

Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors

June 8, 2021

PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia

May 25, 2021

New Data Shows Devastating Impact of AADC Deficiency on Caregivers

May 16, 2021

PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results

May 3, 2021

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results

April 19, 2021

PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing

April 13, 2021

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

April 6, 2021

PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award

April 6, 2021

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™

March 31, 2021

PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy

March 29, 2021

PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies

March 14, 2021

Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine

March 8, 2021

PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

February 24, 2021

PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19

February 16, 2021

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

February 10, 2021

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category

January 13, 2021

PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy

December 3, 2020

PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia

November 29, 2020

PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications

November 17, 2020

PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program

November 16, 2020

PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

October 28, 2020

PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

October 25, 2020

PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts

October 21, 2020

PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders

September 8, 2020

PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations

September 7, 2020

PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)

August 25, 2020

PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy

August 16, 2020

PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older

August 6, 2020

PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

August 4, 2020

PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million

July 19, 2020

PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857

July 7, 2020

PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy

June 28, 2020

PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19

June 16, 2020

PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy

June 11, 2020

PTC Therapeutics Launches New "Talent Pipeline Program" to Help Students who Graduated During the 2020 COVID-19 Pandemic

June 9, 2020

PTC Therapeutics Successfully Completes Acquisition of Censa Pharmaceuticals

May 31, 2020

PTC Therapeutics, Inc. to Hold Virtual 2020 Annual Meeting of Stockholders

May 26, 2020

PTC Therapeutics to Acquire Censa Pharmaceuticals

May 5, 2020

PTC Therapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

April 29, 2020

Confirmatory Part 2 of FIREFISH Demonstrates Survival and Motor Milestones Not Seen in Natural History in Infants with Type 1 Spinal Muscular Atrophy

April 27, 2020

PTC Therapeutics Announces New Leadership Appointments

April 16, 2020

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2020 Financial Results

April 15, 2020

PTC Announces Regulatory Update on Risdiplam for Spinal Muscular Atrophy (SMA)

April 6, 2020

PTC Therapeutics Announces Management Change

March 15, 2020

PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

March 1, 2020

PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy

February 17, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 33 decks. Every deck is listed under its year.